Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole

Megan R. Barajas, Kristen B. McCullough, Julianna A. Merten, Ross A. Dierkhising, Gabriel T. Bartoo, Shahrukh K. Hashmi, William Hogan, Mark R Litzow, Mrinal M Patnaik, John W. Wilson, Robert C. Wolf, Robert A. Wermers

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Supportive care guidelines recommend antimold prophylaxis in hematopoietic stem cell transplant (HSCT) recipients deemed to have high risk for invasive fungal infection, leading to long-term use of voriconazole after allogeneic HSCT in patients who remain immunocompromised. Voriconazole has been associated with periostitis, exostoses, and fluoride excess in patients after solid organ transplantation, HSCT, and leukemia therapy. The aims of this study were to describe the frequency and clinical presentation of patients presenting with pain and fluoride excess among allogeneic HSCT patients taking voriconazole, to identify when a plasma fluoride concentration was measured with respect to voriconazole initiation and onset of pain, and to describe the outcomes of patients with fluoride excess in the setting of HSCT. A retrospective review was conducted of all adult allogeneic HSCT patients receiving voriconazole at Mayo Clinic in Rochester, Minnesota, between January 1, 2009 and July 31, 2012. Of 242 patients included, 32 had plasma fluoride measured to explore the etiology of musculoskeletal pain. In 31 patients with fluoride measurement while on voriconazole, 29 (93.5%) had elevated levels. The median plasma fluoride was 11.1 μmol/L (range, 2.4 to 24.7). The median duration of voriconazole was 163 days (range, 2 to 1327). The median time to fluoride measurement was 128 days after voriconazole initiation (range, 28 to 692). At 1 year after the start of voriconazole after HSCT, 15.3% of patients had developed pain associated with voriconazole use and 35.7% developed pain while on voriconazole after 2 years. Of the patients with an elevated fluoride level, 22 discontinued voriconazole; pain resolved or improved in 15, stabilized in 3, and worsened in 4 patients. Ten patients continued voriconazole; pain resolved or improved in 7, was attributable to alternative causes in 2, and undefined in 1. Serum creatinine, estimated glomerular filtration rate, alkaline phosphatase, and voriconazole concentration did not predict for fluoride excess and associated pain. Periostitis due to fluoride excess is a common adverse effect of voriconazole that should be considered in patients presenting with pain and is often reversible after drug discontinuation. Alternative antifungal agents with a lower risk for fluoride excess should be considered in patients receiving voriconazole who develop fluoride excess and pain.

Original languageEnglish (US)
Pages (from-to)579-583
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Hematopoietic Stem Cells
Fluorides
Transplants
Pain
Periostitis
Voriconazole
Transplant Recipients
Exostoses
Musculoskeletal Pain
Antifungal Agents
Organ Transplantation
Glomerular Filtration Rate
Alkaline Phosphatase
Creatinine

Keywords

  • Fluoride
  • Hematopoietic stem cell transplantation
  • Musculoskeletal pain
  • Pain
  • Voriconazole

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Barajas, M. R., McCullough, K. B., Merten, J. A., Dierkhising, R. A., Bartoo, G. T., Hashmi, S. K., ... Wermers, R. A. (2016). Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. Biology of Blood and Marrow Transplantation, 22(3), 579-583. https://doi.org/10.1016/j.bbmt.2015.10.021

Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. / Barajas, Megan R.; McCullough, Kristen B.; Merten, Julianna A.; Dierkhising, Ross A.; Bartoo, Gabriel T.; Hashmi, Shahrukh K.; Hogan, William; Litzow, Mark R; Patnaik, Mrinal M; Wilson, John W.; Wolf, Robert C.; Wermers, Robert A.

In: Biology of Blood and Marrow Transplantation, Vol. 22, No. 3, 01.03.2016, p. 579-583.

Research output: Contribution to journalArticle

Barajas, Megan R. ; McCullough, Kristen B. ; Merten, Julianna A. ; Dierkhising, Ross A. ; Bartoo, Gabriel T. ; Hashmi, Shahrukh K. ; Hogan, William ; Litzow, Mark R ; Patnaik, Mrinal M ; Wilson, John W. ; Wolf, Robert C. ; Wermers, Robert A. / Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. In: Biology of Blood and Marrow Transplantation. 2016 ; Vol. 22, No. 3. pp. 579-583.
@article{1d7372d3821947d0bd669b435a82c2e0,
title = "Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole",
abstract = "Supportive care guidelines recommend antimold prophylaxis in hematopoietic stem cell transplant (HSCT) recipients deemed to have high risk for invasive fungal infection, leading to long-term use of voriconazole after allogeneic HSCT in patients who remain immunocompromised. Voriconazole has been associated with periostitis, exostoses, and fluoride excess in patients after solid organ transplantation, HSCT, and leukemia therapy. The aims of this study were to describe the frequency and clinical presentation of patients presenting with pain and fluoride excess among allogeneic HSCT patients taking voriconazole, to identify when a plasma fluoride concentration was measured with respect to voriconazole initiation and onset of pain, and to describe the outcomes of patients with fluoride excess in the setting of HSCT. A retrospective review was conducted of all adult allogeneic HSCT patients receiving voriconazole at Mayo Clinic in Rochester, Minnesota, between January 1, 2009 and July 31, 2012. Of 242 patients included, 32 had plasma fluoride measured to explore the etiology of musculoskeletal pain. In 31 patients with fluoride measurement while on voriconazole, 29 (93.5{\%}) had elevated levels. The median plasma fluoride was 11.1 μmol/L (range, 2.4 to 24.7). The median duration of voriconazole was 163 days (range, 2 to 1327). The median time to fluoride measurement was 128 days after voriconazole initiation (range, 28 to 692). At 1 year after the start of voriconazole after HSCT, 15.3{\%} of patients had developed pain associated with voriconazole use and 35.7{\%} developed pain while on voriconazole after 2 years. Of the patients with an elevated fluoride level, 22 discontinued voriconazole; pain resolved or improved in 15, stabilized in 3, and worsened in 4 patients. Ten patients continued voriconazole; pain resolved or improved in 7, was attributable to alternative causes in 2, and undefined in 1. Serum creatinine, estimated glomerular filtration rate, alkaline phosphatase, and voriconazole concentration did not predict for fluoride excess and associated pain. Periostitis due to fluoride excess is a common adverse effect of voriconazole that should be considered in patients presenting with pain and is often reversible after drug discontinuation. Alternative antifungal agents with a lower risk for fluoride excess should be considered in patients receiving voriconazole who develop fluoride excess and pain.",
keywords = "Fluoride, Hematopoietic stem cell transplantation, Musculoskeletal pain, Pain, Voriconazole",
author = "Barajas, {Megan R.} and McCullough, {Kristen B.} and Merten, {Julianna A.} and Dierkhising, {Ross A.} and Bartoo, {Gabriel T.} and Hashmi, {Shahrukh K.} and William Hogan and Litzow, {Mark R} and Patnaik, {Mrinal M} and Wilson, {John W.} and Wolf, {Robert C.} and Wermers, {Robert A.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.bbmt.2015.10.021",
language = "English (US)",
volume = "22",
pages = "579--583",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole

AU - Barajas, Megan R.

AU - McCullough, Kristen B.

AU - Merten, Julianna A.

AU - Dierkhising, Ross A.

AU - Bartoo, Gabriel T.

AU - Hashmi, Shahrukh K.

AU - Hogan, William

AU - Litzow, Mark R

AU - Patnaik, Mrinal M

AU - Wilson, John W.

AU - Wolf, Robert C.

AU - Wermers, Robert A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Supportive care guidelines recommend antimold prophylaxis in hematopoietic stem cell transplant (HSCT) recipients deemed to have high risk for invasive fungal infection, leading to long-term use of voriconazole after allogeneic HSCT in patients who remain immunocompromised. Voriconazole has been associated with periostitis, exostoses, and fluoride excess in patients after solid organ transplantation, HSCT, and leukemia therapy. The aims of this study were to describe the frequency and clinical presentation of patients presenting with pain and fluoride excess among allogeneic HSCT patients taking voriconazole, to identify when a plasma fluoride concentration was measured with respect to voriconazole initiation and onset of pain, and to describe the outcomes of patients with fluoride excess in the setting of HSCT. A retrospective review was conducted of all adult allogeneic HSCT patients receiving voriconazole at Mayo Clinic in Rochester, Minnesota, between January 1, 2009 and July 31, 2012. Of 242 patients included, 32 had plasma fluoride measured to explore the etiology of musculoskeletal pain. In 31 patients with fluoride measurement while on voriconazole, 29 (93.5%) had elevated levels. The median plasma fluoride was 11.1 μmol/L (range, 2.4 to 24.7). The median duration of voriconazole was 163 days (range, 2 to 1327). The median time to fluoride measurement was 128 days after voriconazole initiation (range, 28 to 692). At 1 year after the start of voriconazole after HSCT, 15.3% of patients had developed pain associated with voriconazole use and 35.7% developed pain while on voriconazole after 2 years. Of the patients with an elevated fluoride level, 22 discontinued voriconazole; pain resolved or improved in 15, stabilized in 3, and worsened in 4 patients. Ten patients continued voriconazole; pain resolved or improved in 7, was attributable to alternative causes in 2, and undefined in 1. Serum creatinine, estimated glomerular filtration rate, alkaline phosphatase, and voriconazole concentration did not predict for fluoride excess and associated pain. Periostitis due to fluoride excess is a common adverse effect of voriconazole that should be considered in patients presenting with pain and is often reversible after drug discontinuation. Alternative antifungal agents with a lower risk for fluoride excess should be considered in patients receiving voriconazole who develop fluoride excess and pain.

AB - Supportive care guidelines recommend antimold prophylaxis in hematopoietic stem cell transplant (HSCT) recipients deemed to have high risk for invasive fungal infection, leading to long-term use of voriconazole after allogeneic HSCT in patients who remain immunocompromised. Voriconazole has been associated with periostitis, exostoses, and fluoride excess in patients after solid organ transplantation, HSCT, and leukemia therapy. The aims of this study were to describe the frequency and clinical presentation of patients presenting with pain and fluoride excess among allogeneic HSCT patients taking voriconazole, to identify when a plasma fluoride concentration was measured with respect to voriconazole initiation and onset of pain, and to describe the outcomes of patients with fluoride excess in the setting of HSCT. A retrospective review was conducted of all adult allogeneic HSCT patients receiving voriconazole at Mayo Clinic in Rochester, Minnesota, between January 1, 2009 and July 31, 2012. Of 242 patients included, 32 had plasma fluoride measured to explore the etiology of musculoskeletal pain. In 31 patients with fluoride measurement while on voriconazole, 29 (93.5%) had elevated levels. The median plasma fluoride was 11.1 μmol/L (range, 2.4 to 24.7). The median duration of voriconazole was 163 days (range, 2 to 1327). The median time to fluoride measurement was 128 days after voriconazole initiation (range, 28 to 692). At 1 year after the start of voriconazole after HSCT, 15.3% of patients had developed pain associated with voriconazole use and 35.7% developed pain while on voriconazole after 2 years. Of the patients with an elevated fluoride level, 22 discontinued voriconazole; pain resolved or improved in 15, stabilized in 3, and worsened in 4 patients. Ten patients continued voriconazole; pain resolved or improved in 7, was attributable to alternative causes in 2, and undefined in 1. Serum creatinine, estimated glomerular filtration rate, alkaline phosphatase, and voriconazole concentration did not predict for fluoride excess and associated pain. Periostitis due to fluoride excess is a common adverse effect of voriconazole that should be considered in patients presenting with pain and is often reversible after drug discontinuation. Alternative antifungal agents with a lower risk for fluoride excess should be considered in patients receiving voriconazole who develop fluoride excess and pain.

KW - Fluoride

KW - Hematopoietic stem cell transplantation

KW - Musculoskeletal pain

KW - Pain

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84952931791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952931791&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2015.10.021

DO - 10.1016/j.bbmt.2015.10.021

M3 - Article

VL - 22

SP - 579

EP - 583

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -